BackAzurRx BioPharma Overview

AzurRx BioPharma Receivables

Latest receivables for AZRX: $1.9M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$1.88M

Peer average

Loading

AzurRx BioPharma Receivables History

Loading

AzurRx BioPharma vs. peers: Receivables Comparison

Loading

AzurRx BioPharma Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

AzurRx BioPharma (AZRX) FAQ

AzurRx BioPharma (AZRX) currently reports a receivables of $1.9M as of March 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore AzurRx BioPharma's receivables history and peer comparisons.

AzurRx BioPharma's receivables changed from $0 to $1.9M (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

AzurRx BioPharma reported $1.9M in receivables as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $1.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for AzurRx BioPharma, and consider following AZRX for alerts when major investors trade the stock.

AzurRx BioPharma is classified in the Healthcare sector. On receivables, it currently shows $1.9M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AZRX with unrelated industries.